The Medicines Co., of Parsippany, N.J., reported that for their second quarter ended June 30, 2016 worldwide net revenue was $54.7 million compared to $74.5 million in the second quarter of 2015. Included in total was $24.4 million of royalty revenues derived from the gross profit of authorized generic sales of Angiomax (bivalirudin) by Sandoz Inc.